A
Alison Armour
Researcher at AstraZeneca
Publications - 30
Citations - 12784
Alison Armour is an academic researcher from AstraZeneca. The author has contributed to research in topics: Gefitinib & Lung cancer. The author has an hindex of 20, co-authored 30 publications receiving 11358 citations. Previous affiliations of Alison Armour include University of Glasgow & Novartis.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka,Yi-Long Wu,Sumitra Thongprasert,Patrapim Sunpaweravong,Swan Swan Leong,Virote Sriuranpong,Tsu Yi Chao,Tsu Yi Chao,Kazuhiko Nakagawa,Da Tong Chu,Nagahiro Saijo,Emma Duffield,Yuri Rukazenkov,Georgina Speake,Haiyi Jiang,Alison Armour,Ka Fai To,James Chih-Hsin Yang,Tony Mok +18 more
TL;DR: EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Journal ArticleDOI
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Yi-Long Wu,Long Yun Li,Claire Watkins,Mark V. Sellers,Elizabeth S. Lowe,Yan Sun,Mei Lin Liao,Kell Østerlind,Martin Reck,Alison Armour,Frances A. Shepherd,Scott M. Lippman,Jean-Yves Douillard +17 more
TL;DR: Non-inferior survival of gefitinib compared with docetaxel is established, suggesting that gef itinib is a valid treatment for pretreated patients with advanced non-small-cell lung cancer.
Journal ArticleDOI
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H Park,Tomasz M. Beer,Alison Armour,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Michael J. Morris,Bernd J. Krause,Vision Investigators +20 more
TL;DR: In this paper, Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer and remains fatal despite recent advances in medical technology.
Journal ArticleDOI
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Jean Yves Douillard,Frances A. Shepherd,Vera Hirsh,Tony Mok,Mark A. Socinski,Radj Gervais,Mei Lin Liao,Helge Bischoff,Martin Reck,Mark V. Sellers,Claire Watkins,Georgina Speake,Alison Armour,Edward S. Kim +13 more
TL;DR: Gefitinib can provide similar overall survival to docetaxel in patients across a broad range of clinical subgroups and that EGFR biomarkers such as mutation status may additionally identify which patients are likely to gain greatest PFS and ORR benefit from gefit inib.